New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma

New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as…

J&J's TECVAYLI cut progression risk by 71% and mortality by 40% vs. standard of care in second-line relapsed myeloma (Phase 3 MajesTEC-9), with 65.9% complete response rate. FDA/EMA filings submitted; approval would establish bispecifics as a new second-line standard, displacing current triplet regimens.